Multiple mechanisms of MYCN dysregulation in Wilms tumour

Oncotarget

Volumn 6, Issue 9, 2015, Pages 7232-7243

  Williams, Richard D ^a   Chagtai, Tasnim ^a   Alcaide German, Marisa ^a   Apps, John ^a   Wegert, Jenny ^b   Popov, Sergey ^c   Vujanic, Gordan ^d   Harm van Tinteren, ^e   van den Heuvel Eibrink, Marry M ^f   Kool, Marcel ^g   Jan de Kraker, ^h   Gisselsson, David ⁱ   Graf, Norbert ^j   Gessler, Manfred ^b   Pritchard Jones, Kathy ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^d CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^e NETHERLANDS CANCER INSTITUTE   (Netherlands)

^f SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^g GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^h ACADEMIC MEDICAL CENTER   (Netherlands)

ⁱ LUND UNIVERSITY   (Sweden)

^j SAARLAND UNIVERSITY   (Germany)

more..

Author keywords

Copy number; DNA methylation; MYCN; Prognostic marker; Wilms tumour

Indexed keywords

AMINO ACID SUBSTITUTION; ANAPLASTIC CARCINOMA; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOGENESIS; CONTROLLED STUDY; COPY NUMBER VARIATION; DNA METHYLATION; EXOME; GAIN OF FUNCTION MUTATION; GENE EXPRESSION PROFILING; GENE FREQUENCY; GENE FUNCTION; GENE LOCUS; GENE OVEREXPRESSION; GENE SEQUENCE; GENE TARGETING; GENETIC ASSOCIATION; GENETIC CONSERVATION; GENETIC VARIABILITY; GERMLINE MUTATION; HETEROZYGOSITY LOSS; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MOLECULAR DYNAMICS; MOLECULAR EVOLUTION; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; NEPHROBLASTOMA; ONCOGENE MYCN; OVERALL SURVIVAL; PARTIAL NEPHRECTOMY; POINT MUTATION; PROTO ONCOGENE; RECURRENCE FREE SURVIVAL; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; TUMOR SUPPRESSOR GENE; DISEASE FREE SURVIVAL; DNA MICROARRAY; DNA MUTATIONAL ANALYSIS; GENE DOSAGE; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; KIDNEY TUMOR; METABOLISM; MUTATION; ONCOGENE MYC; PROGNOSIS; TUMOR RECURRENCE;

MYC PROTEIN; PROTEIN P53; TP53 PROTEIN, HUMAN;

DISEASE-FREE SURVIVAL; DNA METHYLATION; DNA MUTATIONAL ANALYSIS; EXOME; GENE DOSAGE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MYC; GENES, P53; HUMANS; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; MUTATION; NEOPLASM RECURRENCE, LOCAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POINT MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MYC; TUMOR SUPPRESSOR PROTEIN P53; WILMS TUMOR;

EID: 84924682507     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3377     Document Type: Article

References (54)

1. Bonetta L, Kuehn SE, Huang A, Law DJ, Kalikin LM, Koi M, Reeve AE, Brownstein BH, Yeger H, Williams BR and et al. Wilms tumor locus on 11p13 defined by multiple CpG island-associated transcripts. Science. 1990; 250(4983):994-997.
2. Call KM, Glaser T, Ito CY, Buckler AJ, Pelletier J, Haber DA, Rose EA, Kral A, Yeger H, Lewis WH and et al. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell. 1990; 60(3):509-520.
3. Gessler M, Poustka A, Cavenee W, Neve RL, Orkin SH and Bruns GA. Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumping. Nature. 1990; 343(6260):774-778.
4. Haber DA, Buckler AJ, Glaser T, Call KM, Pelletier J, Sohn RL, Douglass EC and Housman DE. An internal deletion within an 11p13 zinc finger gene contributes to the development of Wilms' tumor. Cell. 1990; 61(7):1257-1269.
5. Huang A, Campbell CE, Bonetta L, McAndrews-Hill MS, Chilton-MacNeill S, Coppes MJ, Law DJ, Feinberg AP, Yeger H and Williams BR. Tissue, developmental, and tumor-specific expression of divergent transcripts in Wilms tumor. Science. 1990; 250(4983):991-994.
6. Rose EA, Glaser T, Jones C, Smith CL, Lewis WH, Call KM, Minden M, Champagne E, Bonetta L, Yeger H and et al. Complete physical map of the WAGR region of 11p13 localizes a candidate Wilms' tumor gene. Cell. 1990; 60(3):495-508.
7. Koesters R, Ridder R, Kopp-Schneider A, Betts D, Adams V, Niggli F, Briner J and von Knebel Doeberitz M. Mutational activation of the beta-catenin proto-oncogene is a common event in the development of Wilms' tumors. Cancer Res. 1999; 59(16):3880-3882.
8. Maiti S, Alam R, Amos CI and Huff V. Frequent association of beta-catenin and WT1 mutations in Wilms tumors. Cancer Res. 2000; 60(22):6288-6292.
9. Rivera MN, Kim WJ, Wells J, Driscoll DR, Brannigan BW, Han M, Kim JC, Feinberg AP, Gerald WL, Vargas SO, Chin L, Iafrate AJ, Bell DW and Haber DA. An X chromosome gene, WTX, is commonly inactivated in Wilms tumor. Science. 2007; 315(5812):642-645.
10. Bardeesy N, Falkoff D, Petruzzi MJ, Nowak N, Zabel B, Adam M, Aguiar MC, Grundy P, Shows T and Pelletier J. Anaplastic Wilms' tumour, a subtype displaying poor prognosis, harbours p53 gene mutations. Nat Genet. 1994; 7(1):91-97.
11. Williams RD, Al-Saadi R, Chagtai T, Popov S, Messahel B, Sebire N, Gessler M, Wegert J, Graf N, Leuschner I, Hubank M, Jones C, Vujanic G and Pritchard-Jones K. Subtype-specific FBXW7 mutation and MYCN copy number gain in Wilms' tumor. Clinical cancer research : an official journal of the American Association for Cancer Research. 2010; 16(7):2036-2045.
12. White GR, Kelsey AM, Varley JM and Birch JM. Somatic glypican 3 (GPC3) mutations in Wilms' tumour. Br J Cancer. 2002; 86(12):1920-1922.
13. Scott RH, Douglas J, Baskcomb L, Huxter N, Barker K, Hanks S, Craft A, Gerrard M, Kohler JA, Levitt GA, Picton S, Pizer B, Ronghe MD, Williams D, Cook JA, Pujol P, et al. Constitutional 11p15 abnormalities, including heritable imprinting center mutations, cause nonsyndromic Wilms tumor. Nat Genet. 2008; 40(11):1329-1334.
14. Torrezan GT, Ferreira EN, Nakahata AM, Barros BD, Castro MT, Correa BR, Krepischi AC, Olivieri EH, Cunha IW, Tabori U, Grundy PE, Costa CM, de Camargo B, Galante PA and Carraro DM. Recurrent somatic mutation in DROSHA induces microRNA profile changes in Wilms tumour. Nat Commun. 2014; 5:4039.
15. Schumacher V, Schneider S, Figge A, Wildhardt G, Harms D, Schmidt D, Weirich A, Ludwig R and Royer-Pokora B. Correlation of germ-line mutations and two-hit inactivation of the WT1 gene with Wilms tumors of stromal-predominant histology. Proc Natl Acad Sci U S A. 1997; 94(8):3972-3977.
16. Hing S, Lu YJ, Summersgill B, King-Underwood L, Nicholson J, Grundy P, Grundy R, Gessler M, Shipley J and Pritchard-Jones K. Gain of 1q is associated with adverse outcome in favorable histology Wilms' tumors. Am J Pathol. 2001; 158(2):393-398.
17. Natrajan R, Williams RD, Hing SN, Mackay A, Reis-Filho JS, Fenwick K, Iravani M, Valgeirsson H, Grigoriadis A, Langford CF, Dovey O, Gregory SG, Weber BL, Ashworth A, Grundy PE, Pritchard-Jones K, et al. Array CGH profiling of favourable histology Wilms tumours reveals novel gains and losses associated with relapse. J Pathol. 2006; 210(1):49-58.
18. Grundy PE, Breslow NE, Li S, Perlman E, Beckwith JB, Ritchey ML, Shamberger RC, Haase GM, D'Angio GJ, Donaldson M, Coppes MJ, Malogolowkin M, Shearer P, Thomas PR, Macklis R, Tomlinson G, et al. Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005; 23(29):7312-7321.
19. McQuaid S and O'Meara A. N-myc oncogene amplification in paediatric tumours. Ir J Med Sci. 1990; 159(6):172-174.
20. Norris MD, Brian MJ, Vowels MR and Stewart BW. N-myc amplification in Wilms' tumor. Cancer Genet Cytogenet. 1988; 30(1):187-189.
21. Schaub R, Burger A, Bausch D, Niggli FK, Schafer BW and Betts DR. Array comparative genomic hybridization reveals unbalanced gain of the MYCN region in Wilms tumors. Cancer Genet Cytogenet. 2007; 172(1):61-65.
22. Williams RD, Al-Saadi R, Natrajan R, Mackay A, Chagtai T, Little S, Hing SN, Fenwick K, Ashworth A, Grundy P, Anderson JR, Dome JS, Perlman EJ, Jones C and Pritchard-Jones K. Molecular profiling reveals frequent gain of MYCN and anaplasia-specific loss of 4q and 14q in Wilms tumor. Genes, chromosomes & cancer. 2011; 50(12):982-995.
23. Perotti D, Spreafico F, Torri F, Gamba B, D'Adamo P, Pizzamiglio S, Terenziani M, Catania S, Collini P, Nantron M, Pession A, Bianchi M, Indolfi P, D'Angelo P, Fossati-Bellani F, Verderio P, et al. Genomic profiling by whole-genome single nucleotide polymorphism arrays in Wilms tumor and association with relapse. Genes, chromosomes & cancer. 2012; 51(7):644-653.
24. Pfister S, Remke M, Benner A, Mendrzyk F, Toedt G, Felsberg J, Wittmann A, Devens F, Gerber NU, Joos S, Kulozik A, Reifenberger G, Rutkowski S, Wiestler OD, Radlwimmer B, Scheurlen W, et al. Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009; 27(10):1627-1636.
25. Aldosari N, Bigner SH, Burger PC, Becker L, Kepner JL, Friedman HS and McLendon RE. MYCC and MYCN oncogene amplification in medulloblastoma. A fluorescence in situ hybridization study on paraffin sections from the Children's Oncology Group. Archives of pathology & laboratory medicine. 2002; 126(5):540-544.
26. Williamson D, Lu YJ, Gordon T, Sciot R, Kelsey A, Fisher C, Poremba C, Anderson J, Pritchard-Jones K and Shipley J. Relationship between MYCN copy number and expression in rhabdomyosarcomas and correlation with adverse prognosis in the alveolar subtype. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005; 23(4):880-888.
27. Pugh TJ, Morozova O, Attiyeh EF, Asgharzadeh S, Wei JS, Auclair D, Carter SL, Cibulskis K, Hanna M, Kiezun A, Kim J, Lawrence MS, Lichenstein L, McKenna A, Pedamallu CS, Ramos AH, et al. The genetic landscape of high-risk neuroblastoma. Nat Genet. 2013; 45(3):279-284.
28. Forbes SA, Tang G, Bindal N, Bamford S, Dawson E, Cole C, Kok CY, Jia M, Ewing R, Menzies A, Teague JW, Stratton MR and Futreal PA. COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer. Nucleic Acids Res. 2010; 38(Database issue):D652-657.
29. Jones DT, Jager N, Kool M, Zichner T, Hutter B, Sultan M, Cho YJ, Pugh TJ, Hovestadt V, Stutz AM, Rausch T, Warnatz HJ, Ryzhova M, Bender S, Sturm D, Pleier S, et al. Dissecting the genomic complexity underlying medulloblastoma. Nature. 2012; 488(7409):100-105.
30. TCGA. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008; 455(7216):1061-1068.
31. Wu J, Jiao Y, Dal Molin M, Maitra A, de Wilde RF, Wood LD, Eshleman JR, Goggins MG, Wolfgang CL, Canto MI, Schulick RD, Edil BH, Choti MA, Adsay V, Klimstra DS, Offerhaus GJ, et al. Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. Proc Natl Acad Sci U S A. 2011; 108(52):21188-21193.
32. Finn RD, Bateman A, Clements J, Coggill P, Eberhardt RY, Eddy SR, Heger A, Hetherington K, Holm L, Mistry J, Sonnhammer EL, Tate J and Punta M. Pfam: the protein families database. Nucleic Acids Res. 2014; 42(Database issue):D222-230.
33. Kumar P, Henikoff S and Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc. 2009; 4(7):1073-1081.
34. Adzhubei I, Jordan DM and Sunyaev SR. Predicting functional effect of human missense mutations using PolyPhen-2. Curr Protoc Hum Genet. 2013; Chapter 7:Unit7 20.
35. Abecasis GR, Auton A, Brooks LD, DePristo MA, Durbin RM, Handsaker RE, Kang HM, Marth GT and McVean GA. An integrated map of genetic variation from 1,092 human genomes. Nature. 2012; 491(7422):56-65.
36. Popov SD, Vujanic GM, Sebire NJ, Chagtai T, Williams R, Vaidya S and Pritchard-Jones K. Bilateral wilms tumor with TP53-related anaplasia. Pediatr Dev Pathol. 2013; 16(3):217-223.
37. Rakheja D, Chen KS, Liu Y, Shukla AA, Schmid V, Chang TC, Khokhar S, Wickiser JE, Karandikar NJ, Malter JS, Mendell JT and Amatruda JF. Somatic mutations in DROSHA and DICER1 impair microRNA biogenesis through distinct mechanisms in Wilms tumours. Nat Commun. 2014; 2:4802.
38. Wittmann S, Wunder C, Zirn B, Furtwangler R, Wegert J, Graf N and Gessler M. New prognostic markers revealed by evaluation of genes correlated with clinical parameters in Wilms tumors. Genes, chromosomes & cancer. 2008; 47(5):386-395.
39. Fievet A, Belaud-Rotureau MA, Dugay F, Abadie C, Henry C, Taque S, Andrieux J, Guyetant S, Robert M, Dubourg C, Edan C, Rioux-Leclercq N, Odent S and Jaillard S. Involvement of germline DDX1-MYCN duplication in inherited nephroblastoma. Eur J Med Genet. 2013; 56(12):643-647.
40. Turnbull C, Perdeaux ER, Pernet D, Naranjo A, Renwick A, Seal S, Munoz-Xicola RM, Hanks S, Slade I, Zachariou A, Warren-Perry M, Ruark E, Gerrard M, Hale J, Hewitt M, Kohler J, et al. A genome-wide association study identifies susceptibility loci for Wilms tumor. Nat Genet. 2012; 44(6):681-684.
41. Li H and Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009; 25(14):1754-1760.
42. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, Garimella K, Altshuler D, Gabriel S, Daly M and DePristo MA. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010; 20(9):1297-1303.
43. Cibulskis K, Lawrence MS, Carter SL, Sivachenko A, Jaffe D, Sougnez C, Gabriel S, Meyerson M, Lander ES and Getz G. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol. 2013; 31(3):213-219.
44. Wang K, Li M and Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010; 38(16):e164.
45. Robinson JT, Thorvaldsdottir H, Winckler W, Guttman M, Lander ES, Getz G and Mesirov JP. Integrative genomics viewer. Nat Biotechnol. 2011; 29(1):24-26.
46. Thorvaldsdottir H, Robinson JT and Mesirov JP. Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. Brief Bioinform. 2013; 14(2):178-192.
47. Carr IM, Camm N, Taylor GR, Charlton R, Ellard S, Sheridan EG, Markham AF and Bonthron DT. GeneScreen: a program for high-throughput mutation detection in DNA sequence electropherograms. J Med Genet. 2011; 48(2):123-130.
48. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, Hornik K, Hothorn T, Huber W, Iacus S, Irizarry R, Leisch F, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004; 5(10):R80.
49. Aryee MJ, Jaffe AE, Corrada-Bravo H, Ladd-Acosta C, Feinberg AP, Hansen KD and Irizarry RA. Minfi: A flexible and comprehensive Bioconductor package for the analysis of Infinium DNA Methylation microarrays. Bioinformatics. 2014.
50. Smith GK. (2005). Limma: linear models for microarray data. Bioinformatics and Computational Biology Solutions using R and Bioconductor: Springer, New York), pp. 397-420.
51. Du P, Kibbe WA and Lin SM. lumi: a pipeline for processing Illumina microarray. Bioinformatics. 2008; 24(13):1547-1548.
52. Simon R, Lam A, Li MC, Ngan M, Menenzes S and Zhao Y. Analysis of gene expression data using BRB-ArrayTools. Cancer Inform. 2007; 3:11-17.
53. Lingjaerde OC, Baumbusch LO, Liestol K, Glad IK and Borresen-Dale AL. CGH-Explorer: a program for analysis of array-CGH data. Bioinformatics. 2005; 21(6):821-822.
54. Yau C, Mouradov D, Jorissen RN, Colella S, Mirza G, Steers G, Harris A, Ragoussis J, Sieber O and Holmes CC. A statistical approach for detecting genomic aberrations in heterogeneous tumor samples from single nucleotide polymorphism genotyping data. Genome Biol. 2010; 11(9):R92.